Abstract Number: 2141 • 2017 ACR/ARHP Annual Meeting
Quantitative Nailfold Video Capillaroscopy Parameters Correlate with Dermatomyositis Activity and Damage
Background/Purpose: To assess microvascular structure and function in patients with adult dermatomyositis (DM) and juvenile dermatomyositis (JDM), we have designed and built a mobile, high-resolution…Abstract Number: 2142 • 2017 ACR/ARHP Annual Meeting
Autoantibodies Recognizing Cytosolic 5’-Nucleotidase 1A Are Associated with More Severe Disease in Patients with Juvenile Myositis
Background/Purpose: Autoantibodies recognizing cytosolic 5’-nucleotidase 1A (NT5C1A) are present in the sera of adults with myositis and other autoimmune diseases. They are especially prevalent in…Abstract Number: 2143 • 2017 ACR/ARHP Annual Meeting
Circulating Endothelial Cells and Endothelial Activation Markers As Disease Activity Measures in Idiopathic Inflammatory Myopathies
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases with chronic muscle inflammation and microvasculopathy of muscle and skin capillaries. Circulating endothelial cells (CECs),…Abstract Number: 2144 • 2017 ACR/ARHP Annual Meeting
Multiple Serum Cytokine and Chemokine Profiling to Identify Combinational Biomarkers Toward Patients of Polymyositis/Dermatomyositis Complicated with Rapidly Progressive Interstitial Lung Disease
Background/Purpose: Polymyositis (PM)/dermatomyositis (DM) is a chronic inflammatory disorders involved in skeletal muscles. Interstitial lung disease (ILD) complicated with PM/DM patients is often developed as…Abstract Number: 2145 • 2017 ACR/ARHP Annual Meeting
Anti-CXCR3 Antibody Suppresses Inflammation in C Protein-Induced Myositis Model
Background/Purpose: CXCR3 is a chemokine receptor that plays an important role in T cell chemotaxis in human autoimmune diseases. CXCR3, which is activated by ligand…Abstract Number: 2146 • 2017 ACR/ARHP Annual Meeting
CD4+CXCR4+t Cells in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease
Background/Purpose: The clinical and mechanistic relevance of peripheral CD4+CXCR4+ T cells in idiopathic inflammatory myopathy (IIM)-associated interstitial lung disease (IIM-ILD) is not known. Methods: Patients…Abstract Number: 2147 • 2017 ACR/ARHP Annual Meeting
Dysphagia in Inflammatory Myositis: A Study of the Structural and Physiologic Changes Resulting in Disordered Swallowing
Background/Purpose: The prevalence of dysphagia in patients with inflammatory myopathies has been reported to be as high as 60% (1). Aspiration pneumonia is one of…Abstract Number: 2148 • 2017 ACR/ARHP Annual Meeting
Association of the Paraoxonase 1 Q192R Genetic Polymorphism with Disease Activity in Dermatomyositis
Background/Purpose: Injury to the vascular endothelium is implicated in the pathogenesis of dermatomyositis (DM). Normal high density lipoprotein (HDL) protects the vascular endothelium from damage…Abstract Number: 2149 • 2017 ACR/ARHP Annual Meeting
Statin Use in a Longitudinal Cohort of Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Patients(pts) with idiopathic inflammatory myopathies (IIM) have an increased risk of cardiovascular (CV) disease. Statins reduce CV risk but have been associated with myalgias,…Abstract Number: 2150 • 2017 ACR/ARHP Annual Meeting
Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Background/Purpose: Although intensive immunosuppressive treatment are necessary for the severe cases with polymyositis (PM)/dermatomyositis (DM), the prognostic factors or disease activity indices for PM/DM have…Abstract Number: 2151 • 2017 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM)-associated interstitial lung disease (ILD), intensive immunosuppressive treatment are…Abstract Number: 2152 • 2017 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Treatment with or without a Calcineurin Inhibitor in Resistant Inflammatory Myopathy
Background/Purpose : Patients with polymyositis (PM) and dermatomyositis (DM) refractory to glucocorticoid therapy have been treated with a variety of immunosuppressants including mycophenolate mofetil (MMF)…Abstract Number: 2153 • 2017 ACR/ARHP Annual Meeting
Decreased Lean Body Mass and Bone Mineral Density but Increased Body Fat in Myositis Patients Are Associated with Disease Duration, Inflammatory Status, Skeletal Muscle Involvement and Physical Activity
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by inflammation and atrophy of skeletal muscles, pulmonary and articular involvement, which limit the mobility/self-sufficiency of patients, and…Abstract Number: 2154 • 2017 ACR/ARHP Annual Meeting
Efficacy of an Intensive 24-Week Physiotherapy Programme in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data from a Single-Center Controlled Study
Background/Purpose: Involvement of musculoskeletal system (inflammation, atrophy and permanent damage to the muscle) in idiopathic inflammatory myopathies (IIM) leads to impaired function, reduced muscle strength,…Abstract Number: 2155 • 2017 ACR/ARHP Annual Meeting
Myositis As a Complication of Checkpoint Blockade at a Comprehensive Cancer Center
Background/Purpose: Immune checkpoint inhibitor therapy (ICI) has surfaced as a successful and robust treatment option in the fight to end cancer. As we gain more…
